Results 211 to 220 of about 56,538 (251)
Some of the next articles are maybe not open access.
Cyclophosphamide in relapsing remitting multiple sclerosis
The Italian Journal of Neurological Sciences, 19907 patients with relapsing-remitting multiple sclerosis (MS) were subjected to an intensive course of intravenous (I.V.) cyclophosphamide (CY) therapy. All patients received induction therapy with 11 daily doses of 300 mg/m2 and then a single dose every six months for three years.
F, D'Andrea +3 more
openaire +4 more sources
Daclizumab for relapsing remitting multiple sclerosis
Cochrane Database of Systematic Reviews, 2012The anti-CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. Moreover, there are no severe safety concerns arising from clinical testing so far.To assess the efficacy and safety of daclizumab for the clinical progression of patients with relapsing ...
Jia, Liu +3 more
openaire +3 more sources
Rituximab for relapsing-remitting multiple sclerosis
Cochrane Database of Systematic Reviews, 2013This is an update of the Cochrane review "Rituximab for relapsing-remitting multiple sclerosis" (first published in The Cochrane Library 2011, Issue 12).More than 80% of individuals with multiple sclerosis (MS) experience a relapsing-remitting disease course.
Dian, He +5 more
openaire +2 more sources
Executive functions in relapsing-remitting multiple sclerosis
Applied Neuropsychology: Adult, 2023Some studies suggest that patients with relapsing-remitting multiple sclerosis have problems in the functioning of working memory, and more specifically in executive functions, but the available results are still inconsistent. The aim of the present study was to examine executive functioning in multiple sclerosis using classical and representative ...
M. Rosa Elosúa, Noelia Villadangos
openaire +2 more sources
Ibudilast in relapsing-remitting multiple sclerosis
Neurology, 2010Ibudilast is a phosphodiesterase inhibitor influencing inflammation and neurodegeneration in multiple sclerosis (MS). This study evaluated the safety, tolerability, and effects on MRI parameters of 2 different doses of ibudilast in relapsing forms of MS.In this multicenter, double-blind, phase 2 trial, patients with relapsing MS and gadolinium ...
Barkhof, F. +5 more
openaire +3 more sources
Rituximab for relapsing-remitting multiple sclerosis
2011More than 80% of individuals with multiple sclerosis (MS) experience a relapsing-remitting disease course. Approximately ten years after disease onset, an estimated 50% of individuals with relapsing-remitting MS (RR-MS) convert to secondary progressive MS. Quality of life is considerably impaired in early RR-MS.
Dian, He +3 more
openaire +2 more sources
Daclizumab for relapsing remitting multiple sclerosis
2009The anti-CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. Moreover, there are no severe safety concerns arising from clinical testing so far.To assess the efficacy and safety of daclizumab for patients with relapsing remitting multiple sclerosis.We ...
Jia, Liu +4 more
openaire +2 more sources
Immunomonitoring measures in relapsing-remitting multiple sclerosis
Journal of Neuroimmunology, 2004Forty-five patients with relapsing-remitting multiple sclerosis (MS) were examined to determine intracellular cytokine profiles and the surface phenotype of circulating lymphocytes during active, recovery, and stable stages. Active stage patients were characterized by decreases in CD4(+)IL-4(+) Th2 as well as CD4(+)IFN-gamma(+) Th1 cells, when compared
Makoto, Matsui +4 more
openaire +2 more sources
Immunologic therapy for relapsing-remitting multiple sclerosis
Current Neurology and Neuroscience Reports, 2001The treatment of relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis, has been revolutionized in recent years. In addition to effective treatment of acute relapses, therapies are now available to prevent relapses, reduce the burden of disease as seen on magnetic resonance imaging, and possibly even slow the course ...
H J, MacLean, M S, Freedman
openaire +2 more sources
Oral fumarate for relapsing-remitting multiple sclerosis
The Lancet, 2008Udgivelsesdato: 2008/10 ...
Sorensen, P.S., Sellebjerg, F.
openaire +2 more sources